Genprex Faces Nasdaq Delisting Risk Over Compliance Shortfalls

Genprex Inc. faces potential delisting from Nasdaq due to non-compliance with the $1.00 minimum bid price and minimum stockholders’ equity requirements. The company has until October 31, 2025, to meet these criteria. Genprex may need to raise additional capital, but there is no guarantee of securing sufficient financing. Failure to comply could result in delisting.

Genprex Expands Clinical Trials for Lung Cancer Therapy

Genprex announced the expansion of its Acclaim clinical trials for lung cancer therapy by adding a new site at Gabrail Cancer Center in Ohio. The Acclaim-1 trial targets NSCLC with a REQORSA and Tagrisso combination, while Acclaim-3 evaluates REQORSA and Tecentriq for ES-SCLC maintenance. Both trials have FDA Fast Track Designation to expedite development.

USPTO grants patent to Genprex’s Reqorsa gene therapy

The US Patent and Trademark Office has granted Genprex a patent for its Reqorsa gene therapy used with PD-L1 antibodies for cancer treatment, valid until 2037. Genprex is also pursuing similar patents in other countries and is conducting the Acclaim-3 clinical trial for small cell lung cancer, combining Reqorsa with Tecentriq. The trial has FDA orphan drug and fast track designations, with interim analysis expected in 2026.

Genprex Granted U.S. Patent for Reqorsa® Gene Therapy Combined with PD-L1 Antibodies to Treat Cancer

Genprex Inc. has been granted a U.S. patent for its Reqorsa® Gene Therapy combined with PD-L1 antibodies to treat cancer, providing protection until 2037. This patent supports the Acclaim-3 clinical trial for small cell lung cancer. Patents have also been granted in Korea, with applications in Europe, Canada, Brazil, China, and Israel.

Genprex | 10-Q: FY2025 Q3 Revenue: USD 0